GPC3 and hepatocellular carcinoma: In the current series, although a significant difference in the cumulative RFS rate between CK19+/GPC3+ and CK19−/GPC3+ or CK19−/GPC3−HCC was observed, similar phenomenon between CK19−/GPC3+ and CK19−/GPC3− HCC was not found, which implied that a larger sample size is needed to further investigate the effect of this molecular subtyping method in the risk stratification of HCC patients.